Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$17.63 - $21.74 $91,676 - $113,047
-5,200 Reduced 15.62%
28,100 $554,000
Q4 2023

Jan 30, 2024

SELL
$14.37 - $19.07 $27,303 - $36,233
-1,900 Reduced 5.4%
33,300 $584,000
Q3 2023

Oct 26, 2023

SELL
$13.62 - $20.2 $28,602 - $42,420
-2,100 Reduced 5.63%
35,200 $611,000
Q2 2023

Jul 31, 2023

SELL
$10.44 - $16.48 $117,972 - $186,224
-11,300 Reduced 23.25%
37,300 $525,000
Q1 2023

Aug 02, 2023

BUY
$10.7 - $15.79 $120,909 - $178,427
11,300 Added 30.29%
48,600 $522,000
Q1 2023

Apr 27, 2023

BUY
$10.7 - $15.79 $112,349 - $165,795
10,500 Added 27.56%
48,600 $522,000
Q4 2022

Jan 26, 2023

BUY
$11.42 - $17.05 $435,102 - $649,605
38,100 New
38,100 $570,000
Q1 2021

Apr 23, 2021

SELL
$16.68 - $23.97 $221,844 - $318,801
-13,300 Closed
0 $0
Q4 2020

Jan 25, 2021

SELL
$14.8 - $21.15 $273,800 - $391,275
-18,500 Reduced 58.18%
13,300 $235,000
Q3 2020

Dec 14, 2020

BUY
$15.21 - $25.53 $126,243 - $211,899
8,300 Added 35.32%
31,800 $487,000
Q2 2020

Jul 23, 2020

SELL
$15.08 - $26.0 $52,780 - $91,000
-3,500 Reduced 12.96%
23,500 $598,000
Q1 2020

Apr 23, 2020

BUY
$11.0 - $19.76 $148,500 - $266,760
13,500 Added 100.0%
27,000 $417,000
Q2 2019

Jul 25, 2019

BUY
$13.2 - $20.39 $113,520 - $175,354
8,600 Added 175.51%
13,500 $182,000
Q4 2018

Jan 23, 2019

BUY
$16.25 - $28.09 $48,750 - $84,270
3,000 Added 157.89%
4,900 $137,000
Q3 2018

Oct 19, 2018

BUY
$13.23 - $30.93 $25,137 - $58,767
1,900 New
1,900 $48,000

Others Institutions Holding KNSA

About Kiniksa Pharmaceuticals, Ltd.


  • Ticker KNSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,470,400
  • Market Cap $681M
  • Description
  • Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...
More about KNSA
Track This Portfolio

Track Strs Ohio Portfolio

Follow Strs Ohio and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.